Table 4

Effectiveness of the second TNFi (INF, ETA, ADA) at 6 months by reason for switching (primary and secondary inefficacy, intolerance, other)

Reason for discontinuation of first TNFiPrimary inefficacySecondary inefficacyIntoleranceOther
Second TNFiINF [23]ETA [133]ADA [130]INF [29]ETA [165]ADA [143]INF [7]ETA [87]ADA [74]INF [15]ETA [61]ADA [79]
DAS28 baseline5.2±1.3 (18)5.5±1.2* (109)5.1±1.2 (103)4.9±1.2 (23)5.1±1.2 (143)4.8±1.3 (110)4.7±1.5 (7)5.1±1.7 (70)4.4±1.5 (56)4.9±1.6 (11)4.4±1.5 (49)4.0±1.5 (63)
DAS28 6 months4.0±1.4 (17)4.1±1.5 (101)4.3±1.4 (92)3.2±1.5 (18)3.6±1.5 (123)3.9±1.5 (96)3.3±0.8 (3)3.9±1.6 (57)3.4±1.6 (50)4.2±1.5 (10)3.6±1.1 (38)3.5±1.2 (49)
ΔDAS28 6 months−1.1±1.2 (13)−1.5±1.5** (85)−0.8±1.3 (79)−1.3±1.1 (14)−1.6±1.5*** (109)−1.0±1.6 (79)−1.3±1.2 (3)−1.2±1.6 (50)−1.0±1.7 (41)−0.6±2.3 (8)−0.9±1.6 (30)−0.5±1.6 (43)
% Low disease activity of remission29.4% (17)27.2% (103)21.5% (93)44.4% (18)42.3% (130)39.8% (98)66.7% (3)29.8% (57)45.1% (51)27.3% (11)32.5% (40)42.0% (50)
% With DAS28 improvement ≥1.246.2% (13)52.9%† (85)34.2% (79)42.9% (14)61.5%‡ (109)36.7% (79)66.7% (3)56.0% (50)39.0% (41)50% (8)36.7% (30)30.2% (43)
  • The number of patients in each subgroup is shown in brackets.

  • *p=0.08 ETA vs ADA.

  • **p=0.003 ETA vs ADA, p=0.02 after correction for baseline DAS28.

  • ***p=0.03 ETA vs ADA, p=0.02 after correction for baseline DAS28.

  • †p=0.05 ETA vs ADA.

  • ‡p=0.003 ETA vs ADA.

  • ADA, adalimumab; DAS28, disease activity score based on 28-joint status; ΔDAS28, DAS28 change; ETA, etanercept; INF, infliximab; TNFi, tumour necrosis factor inhibitor.